HWM
VRTX icon

Heirloom Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Heirloom Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.5M Buy
23,458
+3,259
+16% +$1.52M 1.89% 18
2025
Q4 		$9.16M Buy
20,199
+233
+1% +$100K 2.12% 18
2025
Q3 		$7.82M Buy
19,966
+333
+2% +$139K 1.89% 20
2025
Q2 		$8.74M Buy
19,633
+80
+0.4% +$36.9K 2.31% 15
2025
Q1 		$9.48M Buy
19,553
+760
+4% +$354K 2.72% 15
2024
Q4 		$7.57M Buy
18,793
+1,185
+7% +$549K 2.27% 15
2024
Q3 		$8.19M Buy
17,608
+321
+2% +$154K 2.55% 15
2024
Q2 		$8.1M Sell
17,287
-264
-2% -$115K 2.63% 13
2024
Q1 		$7.34M Sell
17,551
-284
-2% -$120K 2.5% 14
2023
Q4 		$7.26M Buy
17,835
+384
+2% +$142K 2.79% 13
2023
Q3 		$6.07M Sell
17,451
-316
-2% -$111K 2.7% 13
2023
Q2 		$6.25M Buy
17,767
+736
+4% +$248K 2.72% 13
2023
Q1 		$5.37M Buy
17,031
+4,848
+40% +$1.45M 2.56% 15
2022
Q4 		$3.52M Buy
+12,183
New +$3.71M 2.19% 18
2022
Q2 		$3.49M Buy
11,692
+746
+7% +$200K 2.86% 16
2022
Q1 		$2.7M Sell
10,946
-254
-2% -$60.3K 1.88% 18
2021
Q4 		$2.57M Buy
+11,200
New +$2.18M 2.21% 17

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Heirloom Wealth Management's VRTX Position: Q1 2026 in Review

Heirloom Wealth Management increased its Vertex Pharmaceuticals (VRTX) stake by 16% in Q1 2026, buying an estimated $1.52M and bringing the position to 23,458 shares worth $10.5M. The position accounts for 1.89% of the portfolio, ranked #18.

Heirloom Wealth Management first reported a position in VRTX in Q4 2021 and has held it in 17 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Heirloom Wealth Management held 23,458 shares of Vertex Pharmaceuticals worth $10.5M as of Q1 2026.
  • Heirloom Wealth Management bought 3,259 Vertex Pharmaceuticals shares in Q1 2026, an estimated $1.52M.
  • Vertex Pharmaceuticals made up 1.89% of Heirloom Wealth Management's portfolio in Q1 2026, its #18 holding.
  • Heirloom Wealth Management first reported a position in Vertex Pharmaceuticals in Q4 2021 and has held it in 17 quarters since.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Heirloom Wealth Management's 13F filing for Q1 2026, filed 15 Apr 2026.